Arguing for a Third Way

With two oral multi-kinase inhibitors ahead of it in the market, GlaxoSmithKline plc hopes to position its pazopanib as the agent of choice for front-line treatment of renal cell carcinoma based on a better safety and tolerability profile.

Sutent sunitinib, a small molecule inhibitor of multiple tyrosine kinase receptors from Pfizer Inc., has been widely adopted as the front-line therapy of choice in the U.S. and Europe since its approval in early 2006, according to Debasish Roychowdhury, SVP and head of medicines development in GSK's oncology division. Nexavar sorafenib, a multi-kinase inhibitor from

Read the full 920 word article

User Sign In